Hagen Kennecke, MD
Enriched profileSection Chief and Chief Health Officer, OHSU Knight-Legacy Health Cancer Collaborative · Oregon Health & Science University (OHSU) Knight Cancer Institute
Hagen Kennecke is Section Chief and Chief Health Officer, OHSU Knight-Legacy Health Cancer Collaborative at Oregon Health & Science University (OHSU) Knight Cancer Institute. OpenAlex indexes 302 publications with 9,726 citations (h-index 40); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Hagen Kennecke, MD, MHA, FRCPC, is Section Chief and Chief Health Officer, OHSU Knight-Legacy Health Cancer Collaborative at Oregon Health & Science University (OHSU) Knight Cancer Institute. The public record shows 302 publications with 9,726 citations (h-index 40), centered on Colorectal Cancer Treatments and Studies, Colorectal Cancer Surgical Treatments, Neuroendocrine Tumor Research Advances. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 8 companies.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Colorectal Cancer Treatments and Studies
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 97.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Sponsor: Canadian Cancer Trials Group
- Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Sponsor: Providence Health & Services
- A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Sponsor: Benaroya Research Institute
Industry payments
Updated 16 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20256 payments
- TerSera Therapeutics LLCProgram year20252 payments
- Exelixis Inc.Program year202420 payments$11,071openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
42.9%Corticosteroid42.9%Dexamethasone100%Part D≥11 patientsMetabolism & gastrointestinal
31%Opioid Agonist31%Loperamide100%Part D<11 patientsNervous system
26.2%Phenothiazine26.2%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
102 congress contributions (2006–2026) across AACR, ASCO, ASTRO, SABCS per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.
Endocrine-related cancer
Guideline2026 - Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights.
JCO oncology practice
Article2025 - Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
Journal of clinical oncology
Guideline2025 - Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.
Cancer research communications
Article2025
Most-cited works
by citation count (OpenAlex)- 01Metastatic Behavior of Breast Cancer SubtypesArticle2,256 citations2010
- 02
- 03Breast Cancer Subtypes and the Risk of Local and Regional RelapseArticle1,246 citations2010
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/hagen-kennecke-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/hagen-kennecke-8017a5124
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
swog.org/news-events/news/2026/06/05/meet-swogs-newest-executive-officers
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →swog.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
Editorial & leadership roles
journal and society appointments- Member
NCI GI Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Immediate past chair
NCI Rectal-Anal Task Force
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Prior member
NCI Neuroendocrine Tumor Task Force
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Member
North American Neuroendocrine Tumor Society (NANETS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Member
SWOG Cancer Research Network
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Member
Canadian Cancer Trials Group (CCTG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH